Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.56 |
| ▸ | CCR4 | P51679 | 1/20 | 0.52 |
| ▸ | GRM6 | O15303 | 1/20 | 0.51 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.51 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1819248 | 1.00 | CYP1A2 (0.60) | CYP1A2CYP2C19NPSR1SMN1; SMN2SPHK1 | |
| SCHEMBL2587055 | 1.00 | CYP1A2 (0.60) | CYP1A2CYP2C19NPSR1SMN1; SMN2SPHK1 | |
| Hydrochloric Acid SCHEMBL992441 | 0.98 | CYP1A2 (0.59) | CYP1A2CYP2C19NPSR1SMN1; SMN2SPHK1 | |
| Hydrochloric Acid SCHEMBL20790624 | 0.98 | CYP1A2 (0.59) | CYP1A2CYP2C19NPSR1SMN1; SMN2SPHK1 | |
| Hydrochloric Acid SCHEMBL992443 | 0.98 | CYP1A2 (0.59) | CYP1A2CYP2C19NPSR1SMN1; SMN2SPHK1 | |
| SCHEMBL3713831 | 0.95 | SMN1; SMN2 (0.63) | CYP1A2CYP2C19NPSR1SMN1; SMN2SPHK1 | |
| SCHEMBL16714062 | 0.95 | SMN1; SMN2 (0.63) | CYP1A2CYP2C19NPSR1SMN1; SMN2SPHK1 | |
| SCHEMBL3713829 | 0.95 | SMN1; SMN2 (0.63) | CYP1A2CYP2C19NPSR1SMN1; SMN2SPHK1 | |
| Hydrochloric Acid SCHEMBL2500262 | 0.94 | SMN1; SMN2 (0.61) | CYP1A2CYP2C19NPSR1SMN1; SMN2SPHK1 | |
| Hydrochloric Acid SCHEMBL7742897 | 0.94 | SMN1; SMN2 (0.61) | CYP1A2CYP2C19NPSR1SMN1; SMN2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361490-A1 | COMPOSITION AND METHOD FOR CRYOPRESERVATION OF MITOCHONDRIA | CELLVIE AG (CH) | 2025-11-27 | — | — | US | claimed |
| EP-4535996-A1 | COMPOSITION AND METHOD FOR CRYOPRESERVATION OF MITOCHONDRIA | cellvie AG (CH) | 2025-04-16 | — | — | EP | claimed |
| CN-119365073-A | Compositions and methods for cryopreserving mitochondria | 赛立维公司 | 2025-01-24 | — | — | CN | claimed |
| WO-2023237789-A1 | COMPOSITION AND METHOD FOR CRYOPRESERVATION OF MITOCHONDRIA | CELLVIE AG (CH) | 2023-12-14 | — | — | WO | claimed |
| CN-104098650-B | The synthesis and application of the intermediate of Atosiban | 中国医学科学院药物研究所 | 2019-04-09 | — | — | CN | claimed |
| WO-2017029408-A1 | SOLID STATE FORMS OF SOFOSBUVIR | RATIOPHARM GMBH (DE) | 2017-02-23 | — | — | WO | claimed |
| CN-105705489-A | Compounds useful as immunomodulators | 百时美施贵宝公司 | 2016-06-22 | — | — | CN | claimed |
| EP-2334324-A2 | BBETA (15-42) AND ITS ANALOGUES COMBINED WITH CYCLOSPORINE FOR TREATMENT OF REPERFUSION INJURY | Fibrex Medical Research & Development GmbH (AT) | 2011-06-22 | — | — | EP | claimed |
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | claimed |
| WO-2010043972-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-22 | — | — | WO | claimed |
| EP-2099754-A1 | ION CHANNEL MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2009-09-16 | — | — | EP | claimed |
| WO-2008073929-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | claimed |
| US-20080108830-A1 | Production method of optically active 2-[(N-benzylprolyl)amino]benzo-phenone compound | AJINOMOTO CO. INC (JP) | 2008-05-08 | — | — | US | claimed |
| EP-1918276-A1 | Production method of optically active 2- [ (N-Benzylprolyl) Amino ] Benzophenone compound | Ajinomoto Co., Inc. (JP) | 2008-05-07 | — | — | EP | claimed |
| WO-2005097741-A1 | PROCESS FOR THE RECRYSTALLISATION OF PROLINE DERIVATES | PFIZER LIMITED (GB) | 2005-10-20 | — | — | WO | claimed |
| WO-2005085178-A1 | METHOD OF PREPARING OPTICALLY ACTIVE SERINE DERIVATIVE | ESTECHPHARMA CO., LTD. (KR) | 2005-09-15 | — | — | WO | claimed |
| US-20260117001-A1 | FLUOROPHORE-POLYMER CONJUGATES AND USES THEREOF | ERISYON INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4705292-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-3985732-A | ANXIOLYTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
| US-3968298-A | Process for imparting to natural keratin-containing material a permanent finish rendering the material resistant to damage by insects | CIBA-GEIGY CORPORATION (US) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267697-A1 | ION CHANNEL MODULATORS | CACNA1E, CACNA1A, CACNA1S | CYP1A2 1349/4885CYP2C19 1760/4885NPSR1 590/4885 |
| US-20080108830-A1 | Production method of optically active 2-[(N-benzylprolyl)amino]benzo-phenone compound | NPEPPS, SYMPK, REN | CYP1A2 992/4885CYP2C19 458/4885NPSR1 2415/4885 |
| US-20260117001-A1 | FLUOROPHORE-POLYMER CONJUGATES AND USES THEREOF | QPCTL, QRFPR, CD47 | CYP1A2 4788/4885CYP2C19 4339/4885NPSR1 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.